Clinical Trials Logo

Malignant Skin Melanoma T0 clinical trials

View clinical trials related to Malignant Skin Melanoma T0.

Filter by:
  • None
  • Page 1

NCT ID: NCT05126173 Completed - Clinical trials for Squamous Cell Carcinoma

DERM US and EU Validation Study

Start date: March 15, 2022
Phase:
Study type: Observational

This study aims establish the effectiveness of Image Analysing Algorithm (DERM) to identify melanoma, Squamous Cell Carcinoma (SCC) and Basal Cell Carcinoma (BCC) when used to analyse dermoscopic images of skin lesions within the US and European population.

NCT ID: NCT01168050 Recruiting - Stage IV Melanoma Clinical Trials

Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas.

NILOMEL
Start date: July 2010
Phase: Phase 2
Study type: Interventional

NILOMEL is a phase II multicentric uncontrolled open national trial assessing the efficacy of Nilotinib in first or second line treatment of primary melanomas , stage III unresectable melanomas, or Stage IV melanomas with c-KIT mutation or amplification. The primary objective is overall response rate (partial and complete response) according to RECIST 1.1 criteria, assessed using CT-SCAN (stage IV melanoma) or MRI (unresectable melanoma) after 6 months therapy with Nilotinib 800 mg/d. Secondary objectives include: - Disease control rate (complete, partial response and stable disease) - Metabolic response - Tolerance NCI CTCAE Version 3.0 - Biomarkers associated to response and disease control.